Long-Term Disease Control of a Non-Operable Neuroendocrine Tumor of the Lung with Lanreotide: A Case Study
| Autor: | C. Goor, N. Meireson, F. Van Acker, F. Van Fraeyenhove, Dirk Schrijvers, Caroline Mattelaer, E. De Droogh, D. Galdermans, V. De Ruyter |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Oncology
medicine.medical_specialty Pathology Published online: December 2012 Neuroendocrine tumors Lanreotide lcsh:RC254-282 chemistry.chemical_compound Neuroendocrine tumor Quality of life Internal medicine medicine Lung business.industry lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Carcinoid Comorbidity Disease control medicine.anatomical_structure Somatostatin chemistry Somatostatin analog business |
| Zdroj: | Case Reports in Oncology Case Reports in Oncology, Vol 5, Iss 3, Pp 657-666 (2012) |
| ISSN: | 1662-6575 |
| DOI: | 10.1159/000345695 |
| Popis: | Bronchopulmonary neuroendocrine tumors (NETs) are malignant tumors that represent approximately 20% of all lung cancers. The therapeutic option for advanced or metastatic bronchopulmonary NETs is mainly palliation of symptoms; options need to be individualized and, therefore, rely on the knowledge of multidisciplinary teams. Somatostatin analogs have been widely used in NETs for control of hormonal syndromes and are currently under evaluation for their antiproliferative activity. Here, we present a case of NET of the lung, for which we achieved long-term disease control with a treatment comprising the somatostatin analog lanreotide Autogel® in a patient with limited therapeutic options due to considerable comorbidity, while preserving his quality of life. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|